PTPN11 and cancer: The possibility of deploying SHP2 inhibitors in the treatment of PDAC and other cancers with oncogenic RAS mutations is attracting intense interest, and therefore has increased the importance of understanding the precise mechanism(s) by which of SHP2 contributes to signal transduction.